FigureAsia 35 Under 35 · Healthcare
Teric Tsz Tai Chan
Age 31 · Camera-based physiological measurement · Hong Kong
Scientific cofounder behind a second US 510(k) clearance, adding respiratory-rate measurement to camera-derived pulse and oxygen-saturation functions.
- Approximate age at 31 December 2025
- 31
- Field
- Healthcare
- Country or region
- Hong Kong
- FigureAsia U35 Assessment
- 88.8 / 100
Profile
Career and documented record
Teric Chan has pursued a deceptively difficult clinical proposition: measuring physiological signals through a standard camera without asking the user to wear a sensor. In May 2026, the company's software received a second US 510(k) clearance, this time adding respiratory-rate spot measurement. The regulator's summary describes validation in 107 adults and defines the intended use narrowly. It does not authorize every wellness marker associated with the broader platform.
The milestone matters because non-contact measurement sits at the intersection of optics, signal processing, skin-tone robustness, motion control and medical-device quality. Chan's role as chief scientific officer places him directly across those questions, while his Hong Kong engineering training and company-building record establish a clear Asian centre of gravity. Earlier regulatory work on pulse rate and oxygen saturation created a pathway that the 2026 submission extended.
FigureAsia does not treat clearance as proof that camera measurements improve care on their own. The software supports specified measurements under defined conditions; adoption claims and scan totals remain organization-reported. What Chan has achieved is a repeatable route from research to regulated indication in a field crowded with unvalidated demonstrations.
FigureAsia selection
Why Teric Tsz Tai Chan is on the list
FigureAsia selected Chan because the 2026 clearance is both completed and independently inspectable. It shows scientific continuity, regulatory learning and individual accountability across successive indications. His work also has an access argument: physiological spot checks that require no dedicated wearable could lower friction in telehealth and remote assessment. That possibility earns credit only within the actual indication and validation record, not as a blanket claim of clinical equivalence.
Verified work
The 2025–26 record
Principal milestone
Second US 510(k) decision issued 21 May 2026
Evidence record
Validation summary included 107 adults
Scale or implementation
Respiratory-rate functionality added to previously cleared measurements
Field context
The work in its field
Within camera-based physiological measurement, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
88.8out of 100
Substantive 2025–2026 contribution
18 / 20
The score reflects completed 2025–26 work in camera-based physiological measurement, assessed at the documented maturity of us-cleared spot-measurement software.
Verified impact
13.5 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
8 / 10
The work creates or materially advances a distinctive capability within camera-based physiological measurement rather than relying on title or institutional association.
Field and industry influence
8 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
9 / 10
Named authorship and the documented role of Cofounder and Chief Scientific Officer establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4.5 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
4.5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Hong Kong–educated cofounder of a Hong Kong–founded medical-technology company.
Clinical and scientific validity
6.3 / 7
Clinical and scientific validity is calibrated to us-cleared spot-measurement software, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
7 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
6 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
4 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.